- Lobbying
- takeda AND pharmaceuticals AND america
Lobbying Arrangements Results for 'Takeda Pharmaceuticals America'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details General pharmaceutical issues |
Takeda Pharmaceuticals North America, Inc.
|
in-house lobbying | |||
Details Federal income tax issues. |
Takeda Pharmaceuticals America, Inc.
|
HOLLAND & KNIGHT LLP | |||
Details Tax Reform Technical Corrections and Extenders; Tax Legislation Relating to the Orphan Drug Tax Credit |
Takeda Pharmaceuticals America, Inc.
|
Baker & McKenzie, LLP | |||
Details General issues related to drug research and innovation; General issues related to drug shortages; H.R. 6283, Delinking Revenue from Unfair Gouging Drug Act. |
Takeda Pharmaceuticals America, Inc.
|
PORTERFIELD, FETTIG & SEARS, LLC | |||
Details House (no bill number) and Senate (no bill number) Fiscal Year 2024 Department of Defense Appropriations Bill -- issues related to dengue and vaccine-related matters. House (no bill number) and Sen... |
Klick, Inc. (on behalf of Takeda Pharmaceuticals America, Inc.)
|
FifeStrategies, LLC | |||
Details All provisions related to Medicare's Six Protected Classes policy in Medicare Part D |
Partnership for Part D Access (Informal Coalition)
|
in-house lobbying | |||
Details Issues related to the Base Erosion Anti-Abuse Tax (BEAT) |
Fair Credit Coalition
|
Baker & McKenzie, LLP | |||
Details Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; Proposals related to drug pric... |
Takeda Pharmaceuticals America, Inc.
|
ALPINE GROUP PARTNERS, LLC. | |||
Details Medicare coding and coverage issues for ESAs. |
Affymax, Inc.
Drug research, development and commercialization |
HEALTH POLICY SOURCE, INC. | |||
Details Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169). |
Takeda Pharmaceuticals America, Inc.
|
Tiber Creek Group | |||
Details Policies to enhance patient access to medicines in Medicaid including rebate, waiver policy and funding issues Policies to enhance patient access to medicines in Medicare Proposals related to amend... |
Takeda Pharmaceuticals America, Inc.
|
in-house lobbying | |||
Details Issues related to the implementation of the Patient Protection and Affordable Care Act (P.L.111-148), the pharmaceutical industry, diabetes care and mental health. Issues related to Medicare Part D... |
Takeda Pharmaceuticals America, Inc.
|
Ogilvy Government Relations | |||
Details Rare Disease Issues. General Medicare/Medicaid Issues. Implementation of Inflation Reduction Act of 2022. |
Takeda Pharmaceuticals America, Inc.
|
Todd Strategy Group | |||
Details deficit reduction, ARPA-H, reconciliation H.R. 5376, the Build Back Better Act H.R. 5376, the Build Back Better Act no specific bill, non-interference, 340b, FDASIA implementation, emergency prepa... |
Takeda Pharmaceuticals America, Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Issues related to health care, the Food and Drug Administration (FDA), oncology coverage, mental health, opioid abuse, 340B Program, drug pricing, importation of biopharmaceuticals, insulin price c... |
Takeda Pharmaceuticals America, Inc.
|
Crossroads Strategies, LLC | |||
Details Policies to ensure an adequate supply of blood plasma; Drug safety and drug counterfeiting; Policies affecting pre-existing condition protections; Drug importation; Policies impacting the U.S. res... |
Takeda Pharmaceuticals America, Inc.
|
Williams and Jensen, PLLC |